Early post-transplant follow-up identified a left ventricular hypertrophy so that the patient underwent the screening for Fabry Disease, which identified a heterozygous pathogenic GLA mutation (c.658 C > T [p.R220X]). Here, GLA is linked to left ventricular hypertrophy.